Sustained inhibition of cMET-VEGFR2 signaling using liposome-mediated delivery increases efficacy and reduces toxicity in kidney cancer

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 12, Issue 7, 2016, Pages 1853-1861

  Kulkarni, Ashish A ^a   Vijaykumar, Vijay Elakkya ^a   Natarajan, Siva Kumar ^a   Sengupta, Shiladitya ^a,b,c   Sabbisetti, Venkata S ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HARVARD MIT DIVISION OF HEALTH SCIENCES AND TECHNOLOGY   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

C Met inhibitor; Kinase inhibitor delivery; Liposomes; Renal cell carcinoma

Indexed keywords

AMINO ACIDS; CONTROLLED DRUG DELIVERY; DRUG DOSAGE; ENZYME INHIBITION; TARGETED DRUG DELIVERY; TOXICITY; TUMORS;

C-MET INHIBITORS; CLINICAL TRANSLATION; DOSE LIMITING TOXICITY; INHIBITION OF TUMOR GROWTH; KINASE INHIBITORS; RECEPTOR TYROSINE KINASE; RENAL CELL CARCINOMA; TUMOR XENOGRAFT MODELS;

LIPOSOMES;

CABOZANTINIB; LIPOSOME; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; SCATTER FACTOR RECEPTOR; VASCULOTROPIN RECEPTOR 2; ANTINEOPLASTIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; FIRST PASS EFFECT; KIDNEY CANCER; MALE; MOUSE; NEPHROTOXICITY; NONHUMAN; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TOXICITY TESTING; TUMOR XENOGRAFT; DRUG EFFECTS; HUMAN; KIDNEY NEOPLASMS; PHYSIOLOGY; TISSUE DISTRIBUTION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; HUMANS; KIDNEY NEOPLASMS; LIPOSOMES; TISSUE DISTRIBUTION; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84973470608     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2016.04.002     Document Type: Article

References (41)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013, 63:11-30.
2. Moch H. An overview of renal cell cancer: Pathology and genetics. Semin Cancer Biol 2013, 23:3-9.
3. Flanigan R.C., Campbell S.C., Clark J.I., Picken M.M. Metastatic renal cell carcinoma. Curr Treat Options in Oncol 2003, 4:385-390.
4. Tamaskar I., Dhillon J., Pili R. Resistance to angiogenesis inhibitors in renal cell carcinoma. Clin Adv Hematol Oncol 2011, 9:101-110.
5. van der Veldt A.A., Meijerink M.R., van den Eertwegh A.J., et al. Sunitinib for treatment of advanced renal cell cancer: Primary tumor response. Clin Cancer Res 2008, 14:2431-2436.
6. Rasmussen N., Rathmell W.K. Looking beyond inhibition of VEGF/mTOR: Emerging targets for renal cell carcinoma drug development. Curr Clin Pharmacol 2011, 6:199-206.
7. Flaherty K.T., Puzanov I. Building on a foundation of VEGF and mTOR targeted agents in renal cell carcinoma. Biochem Pharmacol 2010, 80:638-646.
8. Bergers G., Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008, 8:592-603.
9. Rini B.I., Atkins M.B. Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol 2009, 10:992-1000.
10. Schor-Bardach R., Alsop D.C., Pedrosa I., et al. Does arterial spin-labeling MR imaging-measured tumor perfusion correlate with renal cell cancer response to antiangiogenic therapy in a mouse model?. Radiology 2009, 251:731-742.
11. Figlin R.A., Kaufmann I., Brechbiel J. Targeting PI3K and mTORC2 in metastatic renal cell carcinoma: new strategies for overcoming resistance to VEGFR and mTORC1 inhibitors. Int J Cancer 2013, 133:788-796.
12. Moccia A.A., Donaldson J., Chhanabhai M., et al. International Prognostic Score in advanced-stage Hodgkin's lymphoma: Altered utility in the modern era. J Clin Oncol 2012, 30:3383-3388.
13. Paez-Ribes M., Allen E., Hudock J., et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009, 15:220-231.
14. Pennacchietti S., Michieli P., Galluzzo M., Mazzone M., Giordano S., Comoglio P.M. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 2003, 3:347-361.
15. Choueiri T.K., Vaishampayan U., Rosenberg J.E., et al. Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol 2013, 31:181-186.
16. Ciamporcero E., Miles K.M., Adelaiye R., et al. Combination strategy targeting VEGF and HGF/c-met in human renal cell carcinoma models. Mol Cancer Ther 2015, 14:101-110.
17. Sharpe K., Stewart G.D., Mackay A., et al. The effect of VEGF-targeted therapy on biomarker expression in sequential tissue from patients with metastatic clear cell renal cancer. Clin Cancer Res 2013, 19:6924-6934.
18. Rong S., Segal S., Anver M., Resau J.H., Vande Woude G.F. Invasiveness and metastasis of NIH 3 T3 cells induced by Met-hepatocyte growth factor/scatter factor autocrine stimulation. Proc Natl Acad Sci U S A 1994, 91:4731-4735.
19. Abounader R., Laterra J. Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis. Neuro-Oncology 2005, 7:436-451.
20. Afrimzon E., Deutsch A., Shafran Y., et al. Intracellular esterase activity in living cells may distinguish between metastatic and tumor-free lymph nodes. Clin Exp Metastasis 2008, 25:213-224.
21. Nakaigawa N., Yao M., Baba M., et al. Inactivation of von Hippel-Lindau gene induces constitutive phosphorylation of MET protein in clear cell renal carcinoma. Cancer Res 2006, 66:3699-3705.
22. Harshman L.C., Choueiri T.K. Targeting the hepatocyte growth factor/c-Met signaling pathway in renal cell carcinoma. Cancer J 2013, 19:316-323.
23. Gibney G.T., Aziz S.A., Camp R.L., et al. c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma. Ann Oncol 2013, 24:343-349.
24. Lindor N.M., Dechet C.B., Greene M.H., et al. Papillary renal cell carcinoma: Analysis of germline mutations in the MET proto-oncogene in a clinic-based population. Genet Test 2001, 5:101-106.
25. Lubensky I.A., Schmidt L., Zhuang Z., et al. Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphological phenotype. Am J Pathol 1999, 155:517-526.
26. Kollmannsberger C., Mitchell T. Selected toxicities of targeted therapies: Presentation and management. Semin Oncol 2013, 40:499-510.
27. Cohen R.B., Oudard S. Antiangiogenic therapy for advanced renal cell carcinoma: Management of treatment-related toxicities. Investig New Drugs 2012, 30:2066-2079.
28. Yakes F.M., Chen J., Tan J., et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther 2011, 10:2298-2308.
29. Viola D., Cappagli V., Elisei R. Cabozantinib (XL184) for the treatment of locally advanced or metastatic progressive medullary thyroid cancer. Future Oncol 2013, 9:1083-1092.
30. Vaishampayan U. Cabozantinib as a novel therapy for renal cell carcinoma. Curr Oncol Rep 2013, 15:76-82.
31. Torres K.E., Zhu Q.S., Bill K., et al. Activated MET is a molecular prognosticator and potential therapeutic target for malignant peripheral nerve sheath tumors. Clin Cancer Res 2011, 17:3943-3955.
32. Choueiri T.K., Pal S.K., McDermott D.F., et al. A phase I study of cabozantinib (XL184) in patients with renal cell cancer. Ann Oncol 2014, 25:1603-1608.
33. Kulkarni A.A., Roy B., Rao P.S., et al. Supramolecular nanoparticles that target phosphoinositide-3-kinase overcome insulin resistance and exert pronounced antitumor efficacy. Cancer Res 2013, 73:6987-6997.
34. Farokhzad O.C., Langer R. Impact of nanotechnology on drug delivery. ACS Nano 2009, 3:16-20.
35. Lammers T., Kiessling F., Hennink W.E., Storm G. Drug targeting to tumors: Principles, pitfalls and (pre-) clinical progress. J Control Release 2012, 161:175-187.
36. Prabhakar U., Maeda H., Jain R.K., et al. Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res 2013, 73:2412-2417.
37. Mayhew E., Ito M., Lazo R. Toxicity of non-drug-containing liposomes for cultured human cells. Exp Cell Res 1987, 171:195-202.
38. Gabizon A., Papahadjopoulos D. Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc Natl Acad Sci U S A 1988, 85:6949-6953.
39. Ciamporcero E., Miles K.M., Adelaiye R., et al. Combination strategy targeting VEGF and HGF/c-met in human renal cell carcinoma models. Mol Cancer Ther 2015, 14:101-110.
40. Immordino M.L., Dosio F., Cattel L. Stealth liposomes: Review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomedicine 2006, 1:297-315.
41. Huang D., Ding Y., Luo W.M., et al. Inhibition of MAPK kinase signaling pathways suppressed renal cell carcinoma growth and angiogenesis in vivo. Cancer Res 2008, 68:81-88.